Market Overview:
The alpha 1 lung disease market comprises products for treatment and management of three genetic disorders – alpha 1 antitrypsin deficiency, cystic fibrosis, and primary ciliary dyskinesia. Alpha 1 antitrypsin deficiency increases risk of lung and liver disease. Cystic fibrosis causes sticky mucus buildup in lungs, pancreas and other organs. Primary ciliary dyskinesia leads to defective cilia in cells that transport mucus and pollutants from lungs. Current treatment options include medications, physiotherapy and in some cases lung transplant. Gene therapy is a new treatment approach that shows promise to cure these disorders by correcting the genetic mutations.
The global Alpha 1 Lung Disease Market is estimated to be valued at US$ 4.99 Bn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/alpha-1-lung-disease-market-6188
Market key trends:
The key trend in the alpha 1 lung disease market is increasing research and development of gene therapy. Gene therapy involves use of corrective genes to replace the faulty ones causing the disorder. Some gene therapy products in clinical trials show potential to cure alpha 1 antitrypsin deficiency and cystic fibrosis permanently. One therapy under review demonstrated improvement in lung function in alpha 1 patients after a single treatment. Major companies are collaborating with biotechs to develop novel gene therapies. Other trend includes development of next-gen therapies combining gene therapy with other modalities. Approval of first gene therapies will be a major advancement in effectively managing these currently incurable genetic conditions.
Porter’s Analysis
Threat of new entrants: The biopharmaceutical industry requires huge capital investments in RD for drug discovery and development. This high capital requirement poses significant entry barriers for new companies.
Bargaining power of buyers: The prevalence of rare lung diseases leads to inelastic demand. Therefore, the bargaining power of large pharmaceutical buyers is relatively low.
Bargaining power of suppliers: Few biologics/biotechnology companies focus on developing treatments for rare lung diseases. This concentration provides existing suppliers with greater bargaining power over drug makers.
Threat of new substitutes: Given the lack of treatment alternatives for many rare lung conditions, the threat of substitute therapies is low currently.
Competitive rivalry: Major pharmaceutical companies intensely compete to develop and commercialize new drugs for orphan lung disease markets.
Key Takeaways
The global Alpha 1 Lung Disease Market is expected to witness high growth, exhibiting CAGR of 18% over the forecast period, due to increasing research development activities for developing effective therapeutic drugs.
Regionally, North America is expected to dominate the global Alpha 1 Lung Disease market owing to rising prevalence of rare pulmonary disorders, strong healthcare infrastructure, and presence of key market players in the region. The Asia Pacific market is anticipated to exhibit the fastest growth rate during the forecast period driven by expanding healthcare expenditure and increasing patient pool in China and India.
Key players operating in the Alpha 1 Lung Disease market are AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Takeda Pharmaceutical, CSL Behring, Vertex Pharmaceuticals, Amgen, Sanofi, GlaxoSmithKline, Gilead Sciences, Eli Lilly, AbbVie, Johnson Johnson, Teva Pharmaceutical, Audentes Therapeutics, Regeneron Pharmaceuticals. These companies are focusing on new drug development and product launches to strengthen their market positions.
